Acquired haemophilia A in the postpartum and risk of relapse in subsequent pregnancies: A systematic literature review

Haemophilia ◽  
2021 ◽  
Vol 27 (2) ◽  
pp. 199-210
Author(s):  
Natacha Dewarrat ◽  
Mathilde Gavillet ◽  
Anne Angelillo‐Scherrer ◽  
Olaia Naveiras ◽  
Francesco Grandoni ◽  
...  
2021 ◽  
Vol 12 ◽  
pp. 204062072110381
Author(s):  
Amandine Hansenne ◽  
Cedric Hermans

Acquired haemophilia A (AHA) is a rare and severe haemorrhagic autoimmune disease caused by autoantibodies directed against factor VIII (FVIII). Treatment is based on two principles, including haemostatic control to compensate FVIII inhibition and eradication of inhibiting antibodies using immunosuppressive therapy. Rapid recognition and proper management are essential to avoid excess morbidity and mortality. Effective and safe treatments can be challenging, given that AHA patients are often elderly, with multiple comorbidities. Emicizumab, a bispecific antibody that mimics the action of FVIII, has proven effective in managing patients with congenital haemophilia, with or without inhibitors. Likewise, its mode of action suggests theoretical efficacy in AHA patients. We herein describe two AHA cases with comorbidities that were treated effectively using emicizumab combined with immunosuppressive therapy. We have also reviewed the current literature regarding the promising use of emicizumab in this indication.


Haemophilia ◽  
2019 ◽  
Vol 25 (5) ◽  
pp. 755-763 ◽  
Author(s):  
Flora Peyvandi ◽  
Fatemeh Tavakkoli ◽  
Diana Frame ◽  
Jennifer Quinn ◽  
Benjamin Kim ◽  
...  

Haemophilia ◽  
2015 ◽  
Vol 21 (4) ◽  
pp. e341-e343 ◽  
Author(s):  
Y. Liang ◽  
R.-N. Lu ◽  
R. Wang ◽  
J.-F. Zhang ◽  
W. Su ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document